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ABSTRACT 
This  is a prospective Laboratory study conducted at both 
Omdurman Teaching Hospital and Khartoum Teaching Hospital, 
from the first of February till mid  April 2006. 
The aim of the study was to assess changes in blood 
coagulation and basic haematological parameters in HIV/AIDS 
patients in SUDAN. 
Fourty patients were included in this study, 22 males& 18  
females, their ages ranged between 18-65 years. 
 Basic haematological parameters namely HB, WBC, platelet 
counts were done. Also porthrombin time , activated partial 
thromboplastin time, antiphospholipid antibodies and CD4 counts, 
were carried out. 
 Anemia was found is 57.5% of patients, but the type of 
anemia were not determined. There was leucopenia in (45%) patients. 
Thrombocytopenia was detected in 20%of patients. 
In haemostatic profile, no changes were detected regarding 
prothrombin time or activated partial thromboplastin time.  IgM 
antiphospholipid antibodies were found   in 22.5% of patients, and 
 VIII
IgG antiphospholipid in 75%of patients. These antibodies were not 
associated with any clinical manifestations. 
CD4 count was done in 35& low in 34 patients(85%) (less 
than200/ul) while normal in 1 patient (2, 5%).  
 The knowledge of these hematological abnormalities in 
HIV/AIDS patients allows more rational care of these patients. 
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INTRODUCTION AND LITERATURE REVIEW  
 
AIDS (Acquired Immune Deficiency Syndrome) is the most 
serious of all infections known to man. Since its discovery in 1981, the 
disease has attracted attention from health care professionals around 
the globe. The disease is now viewed as a threat to social and 
economic fabric of the world community. Currently 30-40 million 
people are infected with HIV most of them are in Sub-Saharan Africa 
and South East Asia. Serious apprehensions about the problem and 
effective preventive measures have reduced its prevalence in the 
developed countries. Despite a global awareness and prevention 
campaign, one person still dies of HIV every 3 minutes around the 
world. Estimated numbers of HIV/AIDS carriers in SUDAN are six 
hundred thousands, but the reported cases are only 11,500 patients.  
1.1. Virology:  
There are two main types of human immunodeficiency 
viruses; HIV-1, HIV-2 & both cause AIDS. They belong to retroviruses 
of Lent viruses Subfamily they are similar in terms of viral properties.  
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HIV-1 contains single-stranded RNA genome that is 9 Kilo 
bases in length and contains 9 genes that can cause 15 different 
protein s.(1) 
The major viral proteins are classified as structural protein 
(Gag, pol and Env) , regulatory protein (Tat and Rev) and accessory 
proteins (Vpu, Vpr, Vif and Nef). The functional structural proteins   
bind to host cell, intracellular synthesis of provirus by reverse 
transcription, provirus integration into host cell genome, and viral 
assembly and release. They do this by encoding the enzymes in Pol 
(protease, transcriptase and integrase, while Gag gene encode 54KD 
precurss*protein that is cleared by viral protease to form viral core 
protein: p24, p17, p9 and p7. The Env gene form the icosahedral virus 
of HIV, this membrane derived from host cell. The surface contain 
glycoprotein 120 that linked to 41 glycoprotein both derived from a 
160 KD pre protein that encoded by ENV gene. 
Three major classes of HIV have emerged: M (main), N (new) 
and O (outlier). Among M group viruses, which account for >90% of 
HIV infections world wide, there are 9 such types called clades, 
designated by Letters A-D, F-H, J and K as well as many recombinant 
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Forms.(-clade B common in America and western Europe, while clade 
A dominant in Africa).(2) 
1.2. Transmission and Risk Factors: 
HIV is transmitted by sexual contacts with infected partner, 
by parental drug use with contaminated needle, by exposure to 
infected blood or blood.(3) 
The primary method of spread of HIV worldwide is by sexual 
exposure whether it heterosexual or homosexual intercourse, this 
factor associated with increased viral burden in semen include 
advanced HIV disease, high HIV-RNA in blood, CD4 count of less 
than 200 ml and presence of seminal fluid leucocytosis.(4)  
In women, factors that influence the level of HIV-1 in female 
genital tract include stage of HIV disease, menstruation, hormonal 
parameter, vaginal secretion, age, HIV-RNA leveling plasma.(5)The 
presence of other  sexually transmitted disease facilitated infection of 
HIV. Sharing needles and syringes is an important mode of 
transmission among drug abusers specially cocaine abusers. Also 
transmission through infected blood products causes a great risk of 
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transmission of HIV and account for the initially high prevalence of 
HIV infection among patients with hemophilia . 
This way of transmission has been sharply reduced by 
modern techniques of screening blood and blood products.   
 Mother to child transmission occur in approximately 25% of 
live birth to HIV-infected mother viral regimens of antiretroviral, can 
reduced the rate of parental transmission by 50% or more. 
Breast feeding is also a risk factor for HIV transmission3. One 
third of cases of mother to child transmission result from breast 
feeding, and risk increase with the duration of breast feeding. Thus 
great recommendation has been made by CDC to reduce the rate of 
transmission from mother to child through many measures, such as 
giving ARV during pregnancy or at delivery or giving ARV to babies 
in the first week of life,(6) also elective cesarean section and avoidance 
of breast feeding.(7) 
 
1.3. Life cycle of HIV:     
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Can be divided into many steps HIV-1 gp 120 bind the CD4 
surface membrane protein, resulting in further binding to the 
chemokine CCR5 receptor. CD4 lymphocyte, monocyte, macrophage, 
Langerhans cells, follicular dendritic cells, megakaryocyte and thymic 
cells express CD4 and chemokine receptors molecules are susceptible 
to infection by HIV-1. Then virus envelope fuses with the host cell 
membrane. 
The HIV life cycle in the host cell can be divided into several 
steps, binding-fusion, entry, transcription, integration, and 
replication.  
 Binding: HIV-binds to cells via enzymes between the HIV 
envelope glycoproteins and the host cell receptors CD4 molecules and 
co-receptors. The receptors are the CD4 antigen found and some T 
lymphocyte and imunophage monocyte, glial cells of the brain and 
Langerhans cells. The co-receptors are CCR5 and CXCR5. These 
receptors and co-receptors determine which cell the HIV virus will 
infect. 
Fusion: The HIV envelope protein gp 120 binds to the host cell 
receptors and co-receptor on the outside of the cell. This is result in 
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insertion of gp 41 into cell member of the host cell, with fusion of two 
members. 
Entry: The virus Particle leaves it members behind 
(uncoating) and the core virus is released into the cytoplasm of the 
host cell. The host cell enzymes infect with the core of the virus, 
resulting in the release of viral enzymes. 
Reverse transcription: For the virus to multiply, the viral 
(single-strand) RNA must first be converted into (double-strand) 
DNA. This is done by the viral enzyme reverse transcriptase, which 
changes the single-strand viral RNA into double-strand DNA.  
Integration and Replication: The viral DNA is then able to 
enter the host nucleus and the viral enzyme integrase is used to insert 
the viral DNA into the host cell's DNA and this is called integration. 
Once a cell is infected, it is remain infected for life because the viral 
genetic material is integrated into the cells DNA. The host cells are 
then used as a machine to produce more viral DNA "replication". 
Budding: The many viral DNA particles (provirus) that are 
produced using the host cell machinery gather at the membrane of 
the CD4 cell. 
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The proviral particles push through the cell membrane by 
budding, taking the lipid bilayer with them, ready to form new virus 
particles. 
Maturation: The gp 160, embedded in the cell membrane, is 
cleared by the enzyme protease to produce functional gp 41, to form a 
mature virus, which is then ready to infect a new cell. 
1.4. Pathogenesis of HIV infection:  
HIV damages the immune system of body, leaving the 
infected person (vulnerable to a variety of infection " called 
opportunistic infection") this impairment includes the decreased 
lymphocyte count mainly CD4, also decreased lymphocyte 
proliferation to soluble antigen,(6,,7) decreased response in 
immunoglobulin  synthesis, impaired and delayed hypersensivity, 
decreased interferon gama production and decreased T cell mediated 
cytotoxic of virally infected cells. 
The depletion of CD4 T cell by HIV results from direct 
cytopathic effect of HIV and CD4. The host immunological response 
against HIV infected lymphocyte also may contribute to progressive 
loss of CD4 lymphocyte by antibody mediated and cytotoxic T cell 
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mediated mechanism. Non infected lymphocyte are also became 
"innocent by standard" targets for immunological destruction by 
binding free gp120 to their surface CD4 protein. Another continuing 
mechanism, include defective production of cytokine IL2 and 
exaggerated expression of inhibitors of T lymphocyte proliferation 
such as "TGFB".(8) 
A number of defects in hum oral immunity have been associated 
with HIV infection, polyclonal hyper agammaglobulinemia, 
regulation of B lymphocyte is associated with increase in 
autoimmune phenomena and associated with increase in risk of B-cell 
lymphoma,(9) in addition to increase frequency of positive 
antiglobulin test, antibodies against, neutrophil, Lymphocyte and 
platelets also been reported. 
Also accessory immune cells, such as monocyte, macrophage 
and follicular cells of lymphocyte express CD4 antigen all are infected 
by HIV. Monocyte and macrophage are resistant to HIV induced 
cytotoxity and serve as chronic reservoir of HIV expression, while 
functional defect in chemotoxis is observed. Progressive loss of 
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follicular cells is observed by time, resulting in increasing plasma, 
viraemia.  
Natural killer "NK cells" activity is decreased on HIV patients 
while their numbers are normal,(9) defect in NK activity result from 
deficiency in signal for cell activation. 
1.5. Diagnosis of HIV Infection: 
Detection of HIV specific antibodies is screening tests: 
1- Screening test by ELSA: 
a. Rapid test.    
b. Simple test. 
 2- Confirmatry  test: 
• Western Blot. 2- Indirect Immune Fluroscene "IFA". 
•  3- Radio Immune.  Prediction early before antibodies. Assay 
"RIPA". 
• Ag detection: it is p24 detected 
• Nuclic Acid Detection: by PCR for proviral DNA RT- PCR to 
detect HIV-RNA. 
1.6. Course and Outcome of HIV: 
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In untreated person with HIV, there is progression of disease 
by gradual depletion of immune function and eventual development 
of rather nonspecific symptoms, followed by specific infection and 
neoplastic disease.(10) 
Primary HIV infection this defined by the time period from 
initial infection with HIV to development of antibody response 
detectable by standard tests occurring in 50- 90% of patients this 
begins 1-3 wk "range 5 days – 3 months" after primary infection and 
usually lasts 1-2 wk. Prominent symptoms include fever 80% , rash 
51% and ulcer 37%, arthralgia 54%, pharyngitis 44%, loss of appetite 
54%, weight loss 32%, malaise 68%, Myalgia 49% and generalized 
lymphadenopathy may occur. These symptoms are similar to 
infectious mononucleosis.(10)All symptoms of this acute retroviral 
syndrome subsided within several weeks, chronic HIV infection is the 
asymptomatic phase of HIV infection or the second phase before 
AIDS. It is defined by the period after acute HIV infection during 
which CD4 count and viral load change dramatically balance between 
replication and immune response of host occur. So there is little or no 
manifestation of HIV infection, this time between initial infection and 
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development of AIDS may take a long period averaging 10 years even 
in absence of treatment. Lastly the advanced symptomatic HIV 
disease or AIDS, this occur with time  with more extensive fatigue, 
fever, weight loss, night sweating and eventually development of 
opportunistic infections , & candidiasis of bronchi, trachea, lung, and 
oesophagus,  and cryptococcosis, cryptosporidium, cytomegalovirus, 
herpes, histoplasmosis, isosporiasis, mycobacterium avium, 
mycobacterium tuberculosis, pneumocystis carinii pneumonia, 
toxoplasma of the brain, progressive multifocal leucoencephapathy 
and many neoplasm such as lymphoma of the brain, immunoblastic 
lymphoma, Kaposi sarcoma , lymphoma of brain and cervical cancer. 
ALL these considered as AIDS defining condition and 
according to the CDC criteria; AIDS is defined by either diagnosis of 
one of AIDS defining condition or by measurement of CD4 count less 
than 200/mm cell (normal between 600-1200 cell). 
By the phase of AIDS median survival life is short less than 5 
years. Some factor affect progression of HIV disease these include 
host factors and viral factors and they altered the course of 
progression of the disease. 
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Whereas infection of HIV is a multi system disease, 
haematological abnormalities are amongst the commonest 
clinicophathological manifestations of AIDS. Pathogenesis of these 
changes is multi factorial including direct invasion by virus, 
aggregates, HIV- related infections, HIV – associated malignancies 
and drugs. 
1.7. Normal hematopoiesis: 
     Pluripotent stem cells in bone marrow are the basic units of 
hematopoiesis and possess dual ability to replicate and also to 
differentiate into committed progenitors i.e. CFU-UEMM under 
influence of various cytokine like GM-CSF, erythropoietin, and 
thrombopoietin giving rise to more committed progenitors. These 
colony forming units eventually generate the mature forms like 
granulocytes monocytes, erythrocytes and platelets respectively. In 
addition to the role of stem cells and hematopoietic factors in 
hematopoiesis,  bone marrow microenvironment is important, this  
includes T cell and   other factors that stimulate normal hematopoietic 
cell lines, these such as stem cell factors, platelets legend, IL3 and pan 
growth factor. They active stem cells and initiate progenitors and act 
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on differentiation. They are all secreted by T lymphocyte, 
Macrophages also secrete TNF and ILI which act on fibroblasts and 
endothelial cells, Fibroblast and endothelial cells secrete GM-(S), 
which secrete G-CSF & MCSF. 
1.7.1. Normal haemostasis and blood coagulation: 
It is the physiological balance that maintains blood in fluid 
state and prevents spontaneous hemorrhage on the one hand and 
intracellular thrombosis on the other hand. It the is result of interplay 
of five major components: platelets, coagulation factors, coagulation 
inhibitors, fibrinolysis and blood vessels.(11) 
Platelets derived from megakarocyte of bone marrow 
circulate at concentration of 150- 400 x 109. They are flattened disc          
2-4 mm in diameter, non nucleated have a surface membrane of 
phospholipids involved in the coagulation reaction. On the 
membrane are receptors for collagen, thrombin, ADP, adrenaline and 
prostacyclin. Invaginated from of this surface membrane are channels 
through which the platelet secretes the contents of its granules these 
granules are two groups’ alpha and dense granules. The alpha 
contain platelet factor B thromboglobulin which are anti heparin & 
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also contain Fibrinogen and factor V & XIII and VWF. The dense 
granules contain 5HT, ADP which enhance platelets aggregation by 
exposure of Fibrinogen binding sites on platelets. 
The main function of platelets is function of primary plug or 
primary homeostasis; this is initiated when platelets adhere, using 
specific platelets collagen receptors glycoprotein llla to collagen fibers 
in vascular endothelium. This adhesion is mediated by VWF which 
link between platelets glycoprotein Lib/IX/X and collagen. The 
platelets are then activated and release the contents of their granules 
into plasma, in turn activating other platelets and white blood cells. 
The platelets undergo a change in their shape which expresses 
a phospholipids surface for the coagulation factors that require it. 
Fibrinogen links adjacent platelets by forming link via glycoprotein 
IIb/IIa. In addition, thrombin activates platelets. 
1.7.2. Coagulation Factors: 
Coagulation cascade involve series of enzymatic reaction 
leading to conversion of soluble plasma fibrinogen to fibrin clot. The 
coagulation factors are primarily synthesized in the liver and are 
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either enzyme precursor factors XII, XI, IX and thrombin or cofactors 
"V and VIII" except fibrinogen which is degraded to form fibrin. 
The enzymatic part from factor XII is a serine protease and 
hydrolyzes peptide bond  this cascade is divided into "extrinsic and 
intrinsic" pathways leading to final common pathway  to form fibrin . 
1.7.3. Coagulation Control: 
The physiological anticoagulant mechanisms fall into two 
main groups which inhibit serine proteases of coagulation "Serpins" 
such as anti thrombin III or heparin cofactor II which degrades 
thrombin, FXa, XIIa, XIa and IXa.  
It is constantly active, but it is adhesion to these factors is 
increased by presence of heparin surface (glycosaminoglycon) or the 
administration of heparin. Quantitive or qualitative deficiency of 
antithrombin (in born or acquired) leads to thrombophilia. Other 
serine protease inhibitors are C1 esterase inhibitors, α2 antiplasmin, 
α2 macroglobublin and tissue factor pathway inhibitors. 
The second group are those that neutralize activated 
coagulation factors (protein C system) which are serine dependant 
protease and composed of protein C,S and thrombomodulin. This 
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degrades the cofactors Va and VIIIa. Quantitive or qualitative 
deficiency of either "protein C or protein S" may lead to 
thrombophilia. Protein C  also enhances fibrinolysis. 
1.7.4. Fibrinolysis:  
Fibrinolysis like coagulation is a normal haemostatic response 
to vascular injury. Plasminogen a B-globulin pro-enzyme in blood & 
tissue fluid is converted to serine protease plasmin by activators 
either from vessel wall (intrinsic activation) or from tissue (extrinsic 
activation). This important route follows the release of tissue 
plasminogen activators (tPA) from endothelial cells: TPA is serine 
proteases that bind to fibrin. This enhances its capacity to convert 
thrombin-blood plasminogen into plasmin. This fibrin dependence of 
tPA strongly localizes plasmin generation by tPA to fibrin clot. 
Release of tPA occur after such stimuli as trauma, excessive or 
emotional stress. Activated protein C stimulates fibrinolysis by 
destroying plasma inhibitor of tPA. On the other hand thrombins 
inhibit firinolysis by activating thrombin-activated fibrinolysis 
inhibitors TAF1. 
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Plasmin is capable of digesting fibrinogen, fibrin, factor V and 
VIII and many other proteins. Cleavage of peptide bonds in fibrin and 
fibrinogen produce small fragments D and E which can be detected in 
plasma of patient with DIC. 
Important natural inhibiters other than plasminogen 
activation inhibitors are α2 antiplasmin and α2 macroglobulin. 
1.8. Anaemia in HIV: 
Anemia in HIV infection is multifactorial; some of the 
causative mechanisms are: 
 
• Anemia of chronic disease. 
• HIV-related infections. 
• Hemolysis. 
• Drug toxicity. 
• Malignant myelo infiltration. 
• Gastrointestinal bleeding. 
• Vitamin B12 deficiency. 
• Hypogonadism 
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• BM failure. 
These are the most frequent causes of anemia in HIV-infected 
patients (12). Red cells are mostly normocytic and normo chromic; 
there may be mild anisocytosis. Primary defect is the failure of the 
bone marrow to produce normal number of erythrocytes (hypo 
plastic anemia). Some of the postulated mechanisms are: 
• Direct toxic effect of HIV on hematopoietic stem cells and bone 
marrow microenvironment. 
• Abnormal expression of inhibitory cytokines. 
• Relative deficiency of erythropoietin. 
• Defective iron metabolism and reutilization. 
 There is a direct cytotoxic effect of HIV on hematopoietic 
stem cells as well as on stromal microenvironment of the bone 
marrow. This leads to decreased production of G-CSF and IL-3 
resulting in defective erythropoiesis.(13). A study from John Hopkins 
School of Medicine showed that treating severe anemia especially 
with erythropoietin reduces the risk of early death in HIV infected 
anemic patients.(14)  
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Inhibitory effect of increased activity of IL-1, TNF- and   IFN-
gama on bone marrow erythropoiesis has also been postulated as a 
contributory factor towards marrow hypoplasia. There is good 
evidence that serum concentration of endogenous IFN-gama 
correlates inversely with the hemoglobin level in patients with HIV 
infection( 15). Secretion of these cytokines is most likely triggered by 
the underlying chronic inflammation .In a  large epidemiological 
study conducted at CDC HIV/AIDS division ,the reports indicate 
that 28% of men & 31% of women with asymptomatic HIV were 
anemic (Hb <14 and ,12g/dl respectively) this rose to 87% &77 
respectively for patients with clinical AIDS.(16) 
Another important mechanism of anemia in AIDS is 
decreased erythropoietin (17). Levels of erythropoietin were elevated in 
HIV-infected persons with anemia; the increase was less than that 
seen in the HIV sero-negative patients with anemia of the same 
severity.(18) 
Iron deficiency is also well documented in patients with 
AIDS. 50% of children with HIV infection have low serum iron.(19) 
Iron deficiency in AIDS has also been linked to intestinal 
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malabsorption as well as poor intake of iron. Chronic gastrointestinal 
infections may also contribute to malabsorption of iron in patients 
with AIDS. 
The opportunistic infections can lead to defective 
hematopoiesis in HIV-infected patients; the commonest being 
Parvovirus B19 and Mycobacterium avium complex (MAC). 
Parvovirus antibodies have been isolated in 64% of HIV-infected 
patients, MAC infection was diagnosed in 18% of patients with HIV 
disease (20). 
Other less common infectious causes of anemia in HIV-
infected patients include T.B, histoplasmosis, and cryptococcosis and 
pneumonocytosis carinii. 
Hemolytic anemia in AIDS is not uncommon; it is develop as 
a consequence of: 
- G6PD deficiency. 
- Hemophagocytic syndrome. 
- Auto-antibodies against RBCs. 
- Thrombtic thrombocytopenic purpura. 
- Coincidence Hepatitis B and C infection. 
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- Hypersplenism due to advanced liver disease. 
Direct anti globulin (coomb's) test is positive in 37% of HIV 
infected patients.(21) Also haemolysis can occur in HIV infected 
patients receiving drugs like Trimethprime sulfamethoxozole and 
daps one particularly in G6PD deficiency. 
Drugs induced anemia constitutes more than 20% of anaemia 
in patient with HIV. The most common drugs are AZT 
(Zidovudine).(22)  Trimethoprim Sulphamethoxazole. AZT usually 
causes macrocytic anemia. Less common causes of anemia like CMV 
colitis and malignancy like Kaposi by gastrointestinal blood loss and 
lymphoma causing anemia by infiltrations of BM. (23) 
Hypogonadism is relatively common in HIV infected men. 
Estimation   is recommended if anemia is associated with signs of 
Hypogondism.(24) 
1.8.1. Neutropenia in HIV infection: 
   This is common in HIV infected person It occurs in 13% of 
patients in asymptomatic-HIV infected persons and rises to 44% in 
clinical AIDS.(25)   
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In a study carried out in 1997, it was suggested that there was 
strong correlation between the level of absolute Neutrophil count 
(ANC) and need for hospitalization by bacterial infection.(26) In a 
detailed study in 62 HIV infected patients, 24% with ANC below 
1000/ml develop infectious complication within 24 hours of the onset 
of neutropenia.(27) It is postulated that there is a 2-3 fold risk of 
bacterial infection in HIV-infection patients with ANC < 1000 cell/ml, 
the risk increases by 7 to 9 times when the count falls below 500 
cell/ml.(28) Other factors associated with increased risk of infection is 
presence of central venous line, recent history of neutropenia and low 
CD4 count. 
In addition to neutropenia defective granulocytic functions 
have also been documented in HIV infection contributing to defective 
phagocytosis. It is however widely believed that these finding are not 
of much clinical significance.(29)  
Some important causes of neutropenia in HIV setting are:- 
- Drug toxicity. 
- HIV-related infection. 
- Nutrional deficiency. 
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- Autoimmune destruction. 
- Malignant infiltration of bone marrow. 
Most of drugs cause direct BM suppression. An autoimmune 
mechanism involving antibodies against white cells has been 
suggested but studies have shown that anti granulocytic antibodies 
are not related to increased incidence of neutropenia in HIV-infected 
persons.(30) 
Wide range of drugs in AIDS causes leucopenia. This is usually 
dose dependent though it has also been reported as an idiosyncratic phenomenon;. 
AZT treated patients develop neutropenia in 16%. Chemotherapy used for 
non Hodgkin’s lymphoma is also a cause of neutropenia in those 
patients& also in patients of Kaposi sarcoma.(31)  
Gancyclovir used for HIV related CMV infection causes 
neutropenia.(32-33) .Pentamidine & trimethoprim- sulfamexozole used 
for PCP (pneumocystic carnii pneumonia).Also  causing neutropenia 
in AIDS patients, like methotrexate, interferon Alfa amophotericinB, 
cyclophosphamide, etc. 
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Also important mechanism of neutropenia is decrease 
numbers of progenitor’s cell, and decrease serum level of colony 
stimulating factors (GC-CSF). 
 
 
1.8.2. Thrombocytopenia in HIV infection:-  
   Association of HIV-infection with thrombocytopenia was 
recognized long ago .In 1984, a physicians' handbook listed 
thrombocytopenia along with fever, weight loss, fatigue and swollen 
lymph glands as a signal that a patient might have AIDS.(34) 
Incidence:-  
Thrombocytopenia is believed to be present in as many as 
40% of HIV-infected person. In approximately 10% of patients, it may 
be the first sign of AIDS.(35) In a multicenter AIDS cohort study among 
1500 HIV positive individuals 6,7% had platelets count of less than 
150,000 ml on at least one semiannual visit.(36) 
In a center for disease control study in 1996(37) one year 
incidence of thrombocytopenia (platelets count < 50,000 ml) in HIV 
infection was  8,7% in clinical AIDS, 3.1% In immunological AIDS 
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(CD4 cell count < 249ml) and 1,7% in non-clinical, non immunological 
HIV-infection (CD4 cell count >700ml). 
Pathophysiology and clinical course:- 
HIV-related thrombocytopenia though often asymptomatic, 
may present with petechiae, ecchymoses, epistaxsis, menorrhagia, 
gingival bleeding and bleeding in the gastrointestinal tract and in the 
CNS. According to a study conducted in 1992, thrombocytopenia in 
AIDS can be divided into four clinical subsets, of 52 HIV patients it 
was noted that 17% had acute ITP like illness, 40% had chronic ITP 
like disease, while 35% and 8% of patients had splenic sequestration 
type and hypoplastic thrombocytopenia respectively. Hence 
thrombocytopenia in HIV infection may be result from defective 
haemtopoisis but in many instances it is due to hematological 
abnormality related to increased platelets destruction.  
Some important mechanisms of HIV associated 
thrombocytopenias are:- 
1- Immune thrombocytopenia "HIV-ITP":- 
ITP in HIV-related patients like ITP in a similar mechanism 
and is operative. Marked increase in platelet associated 1gG, 1gM, C3, 
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C4 level have been demonstrated in blood of HIV-infected persons. 
Cross reactive antibodies between HIV gp 160/120 and platelet gp 
IIb/IIIa have been found. Platelet antibodies are not helpful in 
establishing the diagnosis of immune medicated thrombocytopenia, 
as there are false positive and false negative results. Instead, response 
to treatment with intravenous immunoglobulin"IVIg" and to IV anti 
D is regarded as among reliable diagnostic tools in HIV-ITP. 
2-Defective thrombopoisis: this is thought to be direct 
infection of bone marrow and due to direct suppression of 
megakorocyte by the virus. Megakorocyte express both CD4 and 
CCRS receptors which enable them to engulf HIV particles.(38) 
3- Drug induced thrombocytopenia: the two drugs in the 
treatment of HIV-infection associated thrombocytopenia are 
Gancyclovir and pentamidine. Grancyclovir is associated with dose 
dependent cytopenia including thrombocytopenia. 
4-HIV-related infection: opportunistic infection like 
cryptococcosios also produces thrombocytopenia in HIV-infected 
persons.5- Also neoplastic condition affect bone marrow, can lead to 
thrombocytopenia.6- Other rare causes of thrombocytopenia include 
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alcohol ingestion, splenomegaly, liver disease and Thrombotic 
thrombocytopenic purpura. 
1.8.3. Coagulation abnormalities in HIV/AIDS: 
Coagulation abnormalities in the setting of HIV infection are 
not common though there is an increased risk of thrombosis (39). They 
are still of considerable importance .In the CDC study it was found 
that overall incidence of thrombotic episodes were 2.6 per100 HIV 
infected person.(40,41) The incidence of thrombotic events(42) was 3.31% 
in those younger than 50 years old versus.53%  in those 50 years or 
more. Retrospective study from the University of Connecticut Health   
Center (43) , found 7.6% (10 of 131) HIV-infected with an unexplained 
DVT or pulmonary embolism (PE). The majority of the thrombotic 
events occurred in those with CD4 counts less than 200/mm3, and 
those with the concurrent presence of opportunistic infections or 
acquired immunodeficiency syndrome (AIDS)-related  neoplasm. 
Thus thrombosis is a significant and probably under-recognized 
complication of HIV infection. 
A variety of hemostatic abnormalities have been identified in 
patients with HIV infection that provide mechanisms for 
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hypercoagulable state and increased likelihood of thrombosis. Best 
known are the endothelial-related changes that include the presence 
of antiphospholipid and anti-cardiolipin antibodies and micro- 
angiopathy.(44)Anti phospholipids antibodies (APL) are proteins 
directed against different phosphor-containg lipids .The best known 
of these are anticardiolipin antibodies (APL) and  lupus 
anticoagulants . Studies have shown APL to be present in 82 to92% of 
patients with AIDS .APL are related to increased occurrence of both 
venous and arterial thrombosis. 
Less well publicized are a variety of changes in the physiologic 
anticoagulant system as a result of HIV infection.(45-46) Decreased 
anticoagulant activities due to deficiencies in protein S, protein C, 
antithrombin, and heparin cofactor II, as well as decreased 
fibrinolysis due to increased levels of plasminogen activator inhibitor 
have been well described.  It has been proposed that these change are 
largely the result of disseminated intravascular-coagulopathy and 
endothelial injury/activation.(47,48) Supporting this hypothesis is a 
report from Erbe and colleagues(49) that documented an increased 
incidence of deficiencies in both protein C(50)  and protein S(43) in HIV-
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infect-patients with an acute opportunistic infection, when compared 
to 8% and 54%, respectively, on follow up investigations after the 
acute events. 
Protein S deficiency is the most consistent coagulation 
abnormality in HIV-infected patients (51). The prevalence is reported to 
be as high as 76%.(52,53) Some investigators(54,55) have shown a 
correlation between low protein S levels and low CD4 counts, while 
others(52,53) have not. The prevalence of protein S deficiency (both total 
and functional) was greater in those CD4 counts less than 200/mm3 
compared to those with CD4 counts above 200/mm3.(53)  
The relationship between protein S levels and CD4 counts may 
simply be a reflection of the duration of the HIV infection.(52,53) While 
small case series have reported thrombotic vents in protein S-deficient 
H1V patients, Hassell and colleagues(56) did not find a correlation 
between protein  S deficiency and thrombosis. It must be concluded 
that the significance of low protein S levels in -infected patients is 
indeterminate. 
The frequency of protein S alterations/deficiencies has led to an 
extensive pursuit of potential mechanisms. Protein S is synthesized 
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by the endothelium, hepatocytes, and megakaryocytes. Endothelial 
injury in HIV infection(57,58) has been proposed as a reasonable 
etiologic basis for the decreased protein S in HIV-infected patients. 
Because free protein S is reduced in inflammatory states largely due 
to increased levels of , C4b-binding protein in HIV-infected patients, 
and this issue and found no difference in the C4b-binding protein 
among normal controls, . Sugarman and co-workers  also failed to 
establish a relationship between protein S values and C4b-binding 
protein in HIV-infected children.(54) 
 In addition, increasing IgG anticardiolipin antibody level was 
correlated with decreasing level of free protein S antigen in adults.(52) 
This relationship was not  identified  in children.(53) Despite the data 
in children, a working hypothesis that increased protein S clearance 
occurs secondary to autoimmune antibodies may be operative in the 
high prevalence of protein S deficiency in HIV-infected patients. 
Another potential mechanism of the hypercoagulable state 
relates to platelet activation. Soluble P-selectin, a marker of platelet 
activation, is also noted to be elevated in HIV-infected patients and 
may contribute to the thrombotic tendency.(59,60) Schecter and 
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colleagues(61)reported that the HIV envelope protein, gpl2O, activates 
human arterial smooth muscle cells to express tissue factor, the 
initiator of the coagulation cascade. The activation of smooth muscle 
cells by gp120 may play an important role in the prothrombotic 
phenotype of the HIV with infected patients. 
In two epidemiological studies of thrombosis in HIV-infected 
patients,(43,46) the use of protease inhibitors was associated with 
thrombotic  events .A review of the literature by safe and 
colleagues(43) found 45 HIV/-infected patients with thrombotic events; 
11 of the 45 were taking at least one protease inhibitor. 
Among these 11 patients, portal vein thrombosis developed in 
two that led to portal hypertension and variceal bleeding. The 
offending medication was indinavir, and no bleeding was observed 
after the protease inhibitor was discontinued.(62)An interesting 
suggestion by these authors was that because aspartyl proteases such 
as renin, endothelin, and cathepsin D are involved in the regulation of 
coagulation,(63,64) and because the HIV protease is an aspartyl 
protease, inhibition of the proteases by indinavir may lead to a 
prothrombotic state.  
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Further support for this comes from Henry and colleagues,(65) 
who reported two young patients in whom severe coronary artery 
occlusion developed after starting protease inhibitors. In addition, the 
26-year-old patient (included in the Saif review) had angina 4 weeks 
after starting ritonavir and saquinavir.  
These authors did suggest that lipodystrophy due to the 
protease inhibitors was the cause of the premature coronary artery 
disease; however, the short duration of the therapy would suggest 
that other mechanisms are involved. 
George and colleagues reviewed the other seven patients in the 
Saif review.(66)  PE developed in seven of 650 HIV-infected patients . It 
is noteworthy that protease inhibitors were not available before that 
time. 
 The mean time to the development of venous thromboembolism 
was 72 days after starting a protease inhibitor. 
 No patient had a concurrent infection at the time of the 
thrombotic event. Three patients required high doses of warfarin to 
maintain a therapeutic International Normalized ratio, and the same 
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three patients had recurrent thrombosis or extension of thrombosis 
while on warfarin and the protease inhibitor. 
 One patient had a history of thrombosis (before institution of 
the protease inhibitor); one had recent surgery but was ambulatory 
for 9 weeks; one was obese and had increased anticardiolipin 
antibodies; one had a family history of DVT and also had increased 
anticardiolipin antibodies; one other patient had a family history of 
PE and was also taking hormonal replacement therapy.  
These data can be compared to historical controls before 1996, 
.where only two cases of unexplained DVT were identified in 1050 
patients. 
Saif and colleagues(67) speculated that because the protease 
inhibitors are metabolized by the cytochrome P450 system, they may 
interfere with hepatic regulation of the thrombotic proteins, leading 
to a prothrombotic state in some patients. 
 However, Pulik and colleagues(50) reported, in abstract form, the 
results of coagulation studies in non-hemophiliac HIV-infected 
patients treated with protease inhibitors. 
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 There were no changes in activated partial thromboplastin time, 
prothrombin time, fibrinogen, von Willebrand factor antigen, 
ristocetin cofactor activity, factor VIII activity, or factor XI antigen. 
Majluf- Cruz and colleagues performed a retrospective study of 
their HIV-infected patients.(68,69) Similar to the study by George and 
colleagues,(68,69) the prevalence of venous thromboembolism appeared 
to have increased significantly since the protease inhibitors were 
introduced into clinical practice.  
In addition, they found a high incidence of protein S deficiency 
in this particular patient cohort. However, only functional protein S 
activity was examined; antigenic protein S was not determined.  
While previous studies we reviewed have established a 
quantitative deficiency of protein S, additional data on C4b-binding 
protein and protein S antigen would have been informative.  
Majluf-Cruz and colleagues also reported two patients who had 
acquired transient activated protein C resistance.(69) 
It would have been interesting to know the factor VIII activity at 
the time of the acquired activated protein C resistance because 
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elevated factor VIII can consume the activated protein C added for 
the assay and result in a falsely defined abnormality.  
Elevated factor VIII activity, which can be a result of acute phase 
reaction, is associated with an increased risk of thrombosis.(69)  
And interesting aspect of the Majluf-Cruz report(69) is that the 
use of aspirin in this cohort of thrombophilic patients resulted in no 
further episodes of thrombosis, including those patients who had 
recurrent thromboses while taking oral anticoagulants.  
The Data Collection on Adverse Events of Anti-HIV Drugs 
(DAD) study group recently reported its prospective observational 
study on the effects of combination antiretroviral therapy on the risk 
of myocardial infarction.(70) 
The incidence of myocardial infarction increased with longer 
exposure to combination antiretroviral therapy.  
These observations, along with the P-selection studies,lend 
incidence to the suggestion that platelet activation is an important 
pathophysiologic mechanism of the prothrombotic, state in HIV-
infected patients.  
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To date, there are little formative data on the effect of protease 
inhibitors on platelet function. Such data might provide a basis for 
aspirin use as part of the primary therapy for HIV-infected patients 
with thrombophilia, particularly those placed on therapy, with 
protease inhibitors. 
Cleary a hypercoagulable state and thrombosis are emerging as 
clinical issues in HIV –infected patients. 
Although commonly multifactorial issues are projected as the 
clinical basis and the focus turns to management, the recent growing 
evidence of associated thrombophilia and correlated platelet 
activation as well as potential interactions with therapy with protease 
inhibitors. This lead to importance of examination of HIV infected 
patients.  
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1.9. Objectives: 
1.9.1. General: 
 To find the incidence, of hematological abnormalities, in 
HIV/AIDS patients.   
 
1.9.2. Specific:                       
1. To study & investigate coagulation profile and basic 
hematological parameters in HIV/ AIDS patients. 
2. To find out if laboratory investigation can predict a 
thrombotic events 
3. To find if there an association between CD4 level &some 
hematological parameters.. 
 
1.10. Justification:  
In the literature there is documented evidence of hemorrhagic 
& hypercoagulable state in the HIV infection .This has not been 
looked into in Sudanese patients & it would be important to see if 
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such abnormalities exist so as to be aware of them &diagnose &treat 
them early.    
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MATERIALS AND METHODS 
2.1: Subjects: 
2.1.1. Study design:  
This is a prospective laboratory study. It is conducted at 
Omdurman Teaching Hospital (OTHC) which has the largest center 
for screening and management of patients with HIV/AIDS in Sudan. 
2.1.2. Study duration: 
Data were collected in the period from first of February till the 
mid of April 2006. 
2.1.3. Study Population: 
The study population was known HIV/AIDS patients who 
were on regular follow up at OTHC.40 such patients were studied. 
2.1.4. Inclusion Criteria: 
Any HIV+ve patient,  whether  hospitalized or outpatient. 
2.1.5. Exclusion Criteria: 
1.  Patients less than 18yr. 
2. Those patients who refused testing. 
3. Clinically suspected HIV patient with negative tests. 
2.2. Tools and methods: 
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2.2.1. Consent: See appendix(1) 
Verbal and written was taken from the hospital 
administration (By directors of HIV/AIDS center) and the patients. 
2.2.2. Questionnaire: 
See appendix (2). 
  
2.2.3. Clinical Examination: 
All patients with HIV/AIDS were examined systemically. 
2.2.4. Samples: 
Blood collection under a septic condition from anticubital 
fossa veins, (4 ml) using disposable plastic syringe and divided into 
two containers: 
•  2mls into EDTA container for measurement of hematological 
values and CD4 count. 
• 2mls into Tri Sodium citrate container for coagulation profile 
• 2.2.5.Tests done: 
For the target patients the following tests were done: 
o Hemoglobin (HB). 
o Hematocrit (Hct). 
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o White  cell counts  
o Platelets count. 
o APTT, PT. 
o ApL(IgM&IgG) 
o CD4 counts  
2.2.6.1. Instruments used:  
Hb, Hct, platelets were measured by an automated blood 
counter (Sysmex Kx-21, which also measured white cell counts and 
differentials. 
2.2.6.2. Coagulometer: 
Prothrombin time and activated partial thromboplastin were 
done by semi automated coagulometer. 
2.2.6.3: ELISA: 
Antiphospholipid antibodies were done by ELISA (enzyme 
linked immunosrbant assay) with serum or plasma as sample 
material 
2.2.6.4. CD4 counter machine: 
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CD4 count: Is done by an automated CD4 counter (trade 
name Cyflow counter) . It is an automated blood cell counter used 
specifically for determination of CD4, CD8 and CD45. 
The principle: cells are separated in suspension and stained 
with fluorescent markers and quantity of the dye uptake is 
proportional to the number of antigen molecules of a single cell ,then 
light  from laser excite cell fluorescence and scattered by the cell .This 
fluorescence signal  are displayed in histogram .Normal range of CD4 
lies between 400-1200 cell /L. 
 
2.2.6.1. Sysmex Kx-21 
This is an automated multi- parameter blood cell counter for 
in vitro diagnostic use in clinical laboratories. 
The sysmex Kx-21 processes approximately 60 samples per 
hour and displays on the LCD screen the particle distribution curve of 
WBC, RBC and platelets, along with data of 18 parameters as 
analytical results. 
The sysmex Kx-21 employs three detector blocks and two 
kinds of reagents for blood analysis. The WBC detection block using 
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DC detection method measures the WBC count. The RBC detection 
block also using DC detection method takes the RBC count and 
platelets counts. The Hb detection block measures the HB 
concentration using a non cyanide hemoglobin method.   
 
2.2.6.2. Coagulometer: 
The Amelung KC4 a micro coagulation analyzer is a semi 
automated machine designed for the determination of prothrombin 
time (PT), activated partial thobomoplastine time (APTT), fibrinogen 
concentration determined by Clauss methodology, and other clotting 
assays. 
Principle: KC4 a micro coagulation analyzer measures the 
time from the addition of start reagents to the onset of fibrin 
formation in the cuvette. The specimen 0, I ml of plasma is placed in 
the cuvette and time measurement is stated either automatically or 
manually with the addition of reagent. As the conversion of 
fibrinogen to fibrin occurs, the fibrin strand pulls the ball away from 
its position. This position change of the ball triggers an impulse in the 
magnetic sensor which electronically stops the time measurement. 
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A control sample from a normal person was run with each 
batch of sample. 
• Reagents in PT: thromboplastin+Cacl2. 
• Reagents in PTT: Kaolin+phospholipid solution+Cacl2.  
o The reagents for PT and PTT were purchased from 
DiaMed AG 1785, Switzerland (Appendixes 3 & 4).         
2.2.6.3 Anti phospholipids antibodies: 
This was done by the DRG antiphosholipid screen (ELISA 
3591) for quantitative measurement of IgG or IgM class auto 
antibodies directed against phospholipids. It is an indirect solid phase 
enzyme immunosorbant assay. Micro plate wells are coated with 
mixtures of highly purified negatively- charged phospholipids: 
cardiolipin, phosphotidyl serine, phosphtidyl inositol and 
phosphatidic acid. B2 Glycoprotein 1 as cofactors for binding. Test 
sera or plasma are applied and left for 30 minutes at room 
temperature. 
An antihuman IgG or IgM horseradish peroxidase conjugates 
solution was pipetted into the well. After 15 minutes, washes to 
remove the unbound antibodies. On addition of the substance TMB 
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(3, 3, 5, 5-Teramethyl-benzidine), a colour develops only in those 
wells in which the enzyme is present, indicating the presence of IgG 
or IgM. The reaction is stopped by addition of dilute hydrochloric 
acid and the absorbance is then measured at 450nm. 
The concentration of IgG or IgM is directly proportional to the 
colour intensity of the test sample. See appendix (4). 
2.3. Statistical analysis: 
Data were analyzed by computer software statistical package 
for social science (SPSS) programme. Chi square was used to compare 
the association levels. 
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RESULTS 
Fourty patients were studied , 22 were males & 18 were 
females (Fig.1). 
Distribution of studied group according to age 4 were 
between  18-25 (10%),  15 (37.5%) were between 26-35 ,&18(45%) were 
more than 35 years .  (Fig. 2). 
Distribution of region of studied group; Khartoum 30(75%), 
central Sudan  3(7.5%), Eastern Sudan 2(5%) western Sudan 2(5%) 
and Southern Sudan 3 (7.5%), (Fig. 3). 
 Distribution of marital status of studied groups 39 patients 
were studied: married 27(67.5%), Single 4(10.0%), Divorced 5(12.5%) 
and widowed 3 (7.5%)  (Fig. 4). 
Distribution of occupation and employment 39 patients out of 
40 were studied;  18(45)were employed  and 21(52,5%)  were 
unemployed  (Table 1). 
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Distribution of duration, of illness of studied groups; weeks 
1(2.5%), years 35 (87.5%) out of 40 patients. (Table 2). 
Distribution of symptoms of studied groups; fever was 
present in 17 (42.5%), fatigue in 21(52.5%) , Loss of weight,  in 
29(75.5%) , diarrhea in 21 (57.5%)  (Table 3). 
Distribution of symptoms of bleeding of studied groups; 
Hematuria was found only in one, case 1(2.5%); epistaxis, 1(2.5%), 
melena 1(7.5%) and both Hematuria and malena in 1(2.5%) (Table 5). 
. 
Distribution of drugs taken by the studied groups out of 40 
patients; ARVS were taken by 29 patients (72.5%) and not taken in 
11(27,5%) patients (Table 6). 
  other drugs taken by the studied groups; Septrin by 40-
(100%) Septrin and Anti TB 22(55%), Septrin + Anti TB + Flagyl 2 ( 
5%). 
Distribution of inter current infection among the studied 
group were; Bacterial infection 12(30%), Viral infection in 2 patients 
(5%) and fungal infection in 9 (22.5%) (Table  7). 
.  
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Investigation results: 
Laboratory results: 
Hematological findings in the studied patients: 
White cell count in studied patients: Out of 36 patients 
,18(45%) had low  count, while 15 (37.5%) with normal count and 
3(7.5%) with high cell count. 
Platelet count in studied patient: Out of 33 patient,8(20%) had  
a low platelets count(<150,000 ), 22(55%) had a normal count and 
3(7,5%) had a high count .( Table8). 
Prothrombin time and partial thromboplastin time :   33 
patients were tested & all were  found  to be within normal.   
 (Table 8). 
Anti phospholipids anti bodies in studied patients were 
classified: IgM was normal in 24 patients (60%) and high in 9 (22.5%). 
While IgG was  normal in 3 patients (7.5%) and high in 30 (75.0%) 
(Table  8). 
CD4 count is studied patients: out of 35 patient 34 (85%) were 
low (less 200mm3l) while was normal in 1(12.5%) (Table  8). 
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 Haemoglobin value in studied patients: out of 36 patient, 
23(57.5%) had low Hb level, while 5-12.5% had normal level and 
8(20.0%) with high Hb level (Table 9). 
Tables 10-14 show the correlations between infection and 
IGM, IGG and CD4 groups.   
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Table 1: Distribution of studied population according to 
employment 
Employee  Frequency Percentage 
Yes   18 45.0% 
Not  21 52.5% 
Total  39 97.5% 
 
 
 
 
Table 2: Distribution of studied population according to 
 duration of illness  
Duration  Frequency  Percentage 
Weeks  1 2.5%  
Years 35 87.5%  
Total  36 90.0% 
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Table 3: Distribution of studied population  
according to tribe 
Tribe Frequency  Percentage 
Central  4 10.0%  
North  11 27.5%  
East  3 7.5%  
West  17 42.5%  
South  4 10.0%  
Foreigner   1 2.5 
Total  40  100.0% 
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Table  4: Distribution of studied population  
according to educational level 
Education   Frequency  Percentage 
Khalwa  1 2.5%  
Primary  8 20.0%  
Secondary 10 25.0%  
Higher secondary  12 30.0%  
None  9 22.5% 
Total  40  100.0% 
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Table 4: Distribution of studied population according 
 to symptoms  
Symptoms  Frequency  Percentage 
Fever  17 42.5%  
Fatigue  21 52.5% 
Loss of weight  29 72.5%  
Diarrhoea  21 52.5%  
 
 
Table 5:  Distribution of studied population according 
 to symptoms of bleeding 
 Symptoms of bleeding Frequency  Percentage 
Haematuria  1 2.5%  
Epistaxis  1 2.5%  
Malena  1 2.5%  
Haematuria + malena  1 2.5% 
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Table 6: Distribution of studied population according 
 to ARV used 
ARV uses Frequency  Percentage 
Yes  29 72.5%  
No 11 27.5% 
Total  40 100.0% 
 
 
 
 
 
Table 7: Distribution of studied population 
 According to infection 
Infection Frequency  Percentage 
Yes 15 45.5%  
No 18 54.5%  
Total 33  100%  
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Table 8:  Coagulation profile , APL{antibodes} and CD4 
  Group Normal Low  High  
APL/IgM 24 (60.0%)  -  9 (27.3%)  
APL/IgG  3 (7.5%)  -  30 (75.0%)  
CD4  1 (2.5%)  34 (85.0%)  -  
PTT 33 (82.5%)  - - 
Platelets  22 (55.0%)  8 (20.0%)  3 (7.5%)  
PT  33 (82.5%)  - -  
WBC 18 (45%)  15 (37.5%)  3 (7.5%)  
 
 
 
 
Table 9:  Distribution of Hb in study population  
Hb level  Male  Female  
Normal  11 (27.5%)   5 (12.5%)  
Low  23 (57.5%)  23 (57.5%)  
High  2 (5.0%)  8 (20.0%)  
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Table 10: Correlation between infection and APL IGM group    
IGM Groups Infection   
Normal  High  
Total  
Yes   9 (66.7%)  6 (37.5%)  15 (100%)  
No 15 (83.3%)  3 (16.3%)  18 (100%)  
Total  24 (72.7%)  9 (27.3%)  33 (100%)  
 
     P = 4.09 
 
 
Table 11: Correlation between infection and APL (IgG) group    
IGG Groups Infection  
Normal  High  
Total  
Yes   2 (13.3%)   13 (86.7%)  15 (100%)  
No 1 (5.6%)  17 (94.4%)  18 (100%)  
Total  3 (9.1%)  30 (90.9%)  33 (100%)  
 
     P =  1.36 
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Table 12: Correlation between infection and CD4 group    
CD4 Groups Infection  
Low  Normal 
Total  
Yes   15(100.0%)   0 (0.0%)  15(100.0%)  
No 19 (95.0%)  1 (5.0%)   20 (100.0%)  
Total  34 (97.1%)  1 (2.9%)  35 (100%)  
         P = 0.43 
 
 
 
Table 13: Correlation between TWBCs and CD4 counts    
TWBCs Total  CD4 
Low Normal  High  
 
 
Low   17 
{54.8%} 
11 *(3.5%] 3 (9.7%) 31 (100%)  
Normal  1 (8.3%)   1(100%)  
Total  17 
{53.1%} 
12 (37.5%)  3 ( 9.4%)  33 (100%)  
 
       P = 0.09 
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: Table 14: Corelation between platelets and CD4 counts    
plateltes Total  CD4 
Low Normal  High  
 
 
Low   8  
{28.6%} 
18 
*(64.3%] 
2 (7.1%) 28 (100%)  
Normal  1 (5.3%)   1(100%)  
Total  8 
{27.6%} 
19 (65.5%)  2 ( 6.9%)  29 (100%)  
 
 
P. =0.O7 
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                                     DISCUSSION 
Human immune deficiency virus infection is an illness with 
protean manifestations including hematological abnormalities with 
progression to AIDS state, & more abnormalities in different sites of 
the body is being noticed. Changes in blood coagulation in patients 
with HIV infection and AIDS occur frequently. These changes vary 
considerably between bleeding & hemorrhage to the rarely observed 
complication of hypercoagubility state.(71) 
A variety of mechanisms have been proposed to explain the 
hypercoagubility in HIV & AIDS patients. These include the presence 
of antiphospholipids antibodies (APL) anticardiolipin ACL 
antibodies, decreased natural inhibitors, increased platelets activation 
and others.(71) 
This study was designed to asses the coagulation state and 
other hematological manifestations in Sudanese HIV/AIDS patients. 
The studied populations consist of 22 males and 18 females. And 
most common age group lies between 18-35 years, which is the 
hypersexual age. 
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In the studied group the prevalence of anemia was 57.5%.  
The type of anemia was not determined. The incidence of anemia 
varies according to stages of HIV disease. Another contributing 
factors, such as chemotherapy, race, concurrent illness, and poor 
nutritional status. 
Thrombocytopenia is the most common known hematological 
abnormality causing high morbidity and it affects patients from every 
risk group independantly of age, Sex, or stage of infections (72). This 
thrombocytopenia had been detected in 24.2% of our patients, while 
normal & high platelets were observe in 76.8 without any association 
with bleeding. HIV related thrombocytopenia is often asymptomatic 
but may present with petechiae, ecchymosis, epistaxis,menorrhagia, 
gingival bleeding and bleeding  in the gastrointestinal tract and in the 
CNS.In approximately 10% of the patients ,it may be the first sign of 
AIDS. 
In addition, there are some abnormalities of coagulation, 
mentioned in literature, such as prolongation of activated partial 
thromboplastin time, production of Lupus anticoagulant and 
anticardiolipin antibodies. Such a study was done by Temple school 
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of medicine USA. These changes were not all detected in our study. 
All our patients had normal PT &APPT. Similar results were found 
by Fezoui H, Garnier G, and France. They however found only 
thrombocytopenia and circulating anticoagulant like APL, ACL 
which were asymptomatic. In our study we found that there was high 
level of APL( IgG )in 30 patients out of 33 patients in whom this test 
was done  (75%), and APL(IgM) was high in 9 patients  (22.5%) These 
high levels of APL were not associated with any clinical symptoms. 
This is compatible with the French study. 
 35 patients  hadCD4 done,  low CD4 was found in34 patients( 
85%) while 1 patient (2.5%) had normal CD4. By this test, which is 
newly introduced in Sudan, these patients were categorized as AIDS, 
although most of them are clinically well. Many infections have been 
associated with antiphospholipid antibodies although pathogenic role 
for these antibodies has not usually been obvious except in a few 
cases .These infections could be viral like HIV, Parvovirus B19, 
Varicella, mumps, hepatitis C, and adenovirus .Other bacterial 
infections like leprosy, tuberculosis, salmonella, staphylococci 
,streptococci, spirochetes and other parasitic diseases like malaria, 
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kalazar and toxoplasmosis. These antibodies are rarely found in 
fungal infections. 
In this study correlation between level of the APL antibodies 
(IgM - IgG) and infections (Bacterial, viral, fungal). 
In 15 patients with infection, 9 patients showed normal levels 
of APL( IgM) (66.7%) and 6 patients showed high level (37.7%) . This 
represent that all the infected patients are 45.5%  out of 33 patients 
who did the test. 
Another correlation was made between infection and 
presence of APL ( IgG) .Only 2  patients    had normal level of IgG 
(13.3%) while the 13 had high level (86.7%) this represents 15 patients   
who were infected out of 33 patients who had the test done. HIV 
patients are predisposed to different infection by various 
microorganism, these will increased likelihood to thrombosis, by 
increasing the incidence of APL.  This with other coagulation 
abnormalities increased risk of thrombosis and pulmonary embolism 
.In   our study non of the patients had clinical evidence of thrombosis, 
we have not however done investigations e.g. Doppler, 
Ultrasonography &others  to document venous thrombosis. patients  
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Further more two epidemegical studies showed higher risks for 
patients with AIDS or with a CD4 count < 200 mm3. Thus increased 
risk of DVT in HIV infected patients is probably caused by active on 
going triggering of the immune system by both HIV infection and 
superimposed infection. In this study an association between level of 
CD4 and infection had been done, 15(44.1%) patients had infection. 
All had a low CD4 count out of 35 patients did the test. 
 
An important association between APL antibodies and level 
of CD4 count showed a high level of APL IgM in 7 patients with 
24.1%. In the group with APL IgG level, it is high in 26 patients 
(89.7%) and so it may show great association between the level of 
APL antibodies { IgM  and IgG} with low CD4 counts. 
In addition to this result Stahl found that increased level of 
APL (IgG) antibody was correlated with decreased level of free 
protein S antigen in adults. This decrease in proteins S was noted in 
31(76%) of HIV infected patients. This made it one possible 
mechanism in the pathogenesis of thromboembolism in these patients 
.Another correlation between antiretroviral therapy and APL  
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antibodies that 15 patients receiving ARVs  had normal level of IgM 
and increased in 9 patients (37.5%), while  IgG was  increased in 21 
patients out of 24 patients receiving ARV (87.5%), . Commonly used 
drugs in Sudan these ARVs belong to group of Nucleoside analogue 
and non Nucleosides reverse transcriptase inhibitors, these drugs 
were combined in one drug Triomune and with least side effects but 
anemia & thrombocytopenia &neutropenia were reported. .Evidence 
or association between hypercoagulbility state of HIV/AIDS & using 
protease inhibitors was reported in many studies such Saif and 
Sullivan..  
Many studies in the literature to detect thrombosis or PE in 
these patients using   imaging techniques such on phlebography, V/Q 
scan, Doppler, MRI, ect, as well as laboratory technique.  In this study 
we couldn’t use the techniques to and we use only laboratory data.  
CD4 counter machine is a newly introduced in Sudan. 
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CONCLUSION 
1-HIV/ADIS is affecting haemopoietic systems in many ways. 
2- Overt anemia and thrombocytopenia and neutropenia are 
Commonly seen. 
3- Antiphospholipid antibodies were found in a high proportion 
in these patients specially APL( IgG -75%) and APL( IgM -
12.73%). These could predispose to thrombosis 
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RECOMMENDATIONS  
• Study involving bigger number is needed to confirm our findings.  
• Proper follow up of HIV patients and adjusts prophylactics, 
therapy to opportunistic infections is recommended.  
• Patient with low CD4 <200/mm must follow their Hb, PT, PTT. 
And platelets regularly. 
• Prophylactics antithrombotic in those with thrombophilia reduce 
incidence of recurrent thrombosis 
• Clinical& imaging techniques are needed for follow up of these 
patients for detection   &early treatment thrombosis. 
• Study of other parameters of thrombophilia is needed. 
• Using CD4 as  a new test for categorization of patients of HIV and 
for follow up of these patients. 
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 ﺑﺴﻢ اﷲ اﻟﺮﲪﻦ اﻟﺮﺣﻴﻢ
 muotrahK fo ytisrevinU
 enicideM fo ytlucaF
 draoB seidutS lacideM etaudargtsoP
 ygolohtaP fo tnemtrapeD
 
 
  اﻗﺮار ﺑﺎﻟﻤﻮاﻓﻘﺔ
 اﻟﺴﻼم ﻋﻠﻴﻜﻢ ورﲪﺔ اﷲ وﺑﺮآﺎﺗﻪ
  . ﺠﺎﻤﻌﺔ ﺍﻟﺨﺭﻁﻭﻡ- ﻜﻠﻴﺔ ﺍﻟﻁﺏ-  ﺍﻷﻁﺒﺎﺀ ﺍﻟﺒﺎﺤﺜﻴﻥ ﻓﻲ ﻋﻠﻡ ﺍﻷﻤﺭﺍﺽﻨﺤﻥ ﻤﺠﻤﻭﻋﺔ ﻤﻥ
  ﻜﺭﻴﻡﺍﻟ/.................................................................... ﺍﻷﺨﺕ/ ﺍﻷﺥ
ﻨﺭﺠﻭ ﺃﻥ ﻻ ﺘﻌﺘﺒﺭﻫﺎ ﺍﺨﺘﺒﺎﺭﺍﹰ ﺃﻭ ﺍﻤﺘﺤﺎﻨﺎﹰ ، ﻨﻭﺩ ﻓﻘﻁ ﺃﻥ ﻨﻌﺭﻑ . ﻨﻭﺩ ﺃﻥ ﻨﻭﺠﻪ ﻟﻙ ﺒﻌﺽ ﺍﻻﺴﺌﻠﺔ •
. ﺍﻟﻤﺨﺘﻠﻔﺔ ﻟﺩﻯ ﻤﺭﻀﻰ ﻤﺘﻼﺯﻤﺔ ﻨﻘﺹ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻤﻜﺘﺴﺏ ﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﻤﺘﻌﻠﻘﺔ ﺒﺄﻤﺭﺍﺽ ﺍﻟﺩﻡ ﻭﺍﻷﻭﺭﺍﻡ
 .ﻭﻗﺩ ﺘﻡ ﺍﺨﺘﻴﺎﺭﻙ ﺒﻁﺭﻴﻘﺔ ﻋﺸﻭﺍﺌﻴﺔ ﻭﻟﻴﺴﺕ ﻤﻘﺼﻭﺩﺓ
ﻀﺎﻓﺔ ﺇﻟﻰ ﺃﺨﺫ ﻋﻴﻨﺔ ﻤﻥ ﺍﻟﺩﻡ  ﻟﻌﻤل ﺒﻌﺽ ﺍﻟﻔﺤﻭﺼﺎﺕ ﺴﻨﺴﺄﻟﻙ ﺍﺴﺌﻠﺔ ﻤﺘﻌﻠﻘﺔ ﺒﻙ ﻭﺒﺎﻟﻤﺭﺽ ﺒﺎﻹ •
 .ﺍﻟﻤﻌﻤﻠﻴﺔ ﺍﻟﺘﻰ ﺴﺘﻔﻴﺩﻨﺎ ﻓﻲ ﻤﻌﺭﻓﺔ ﻓﻲ ﻤﻌﺭﻓﺔ ﺘﻐﻴﺭﺍﺕ ﺍﻟﻤﺭﺽ
 ﺍﺠﺎﺒﺎﺘﻙ ﺴﺘﻜﻭﻥ ﻓﻲ ﻏﺎﻴﺔ ﺍﻟﺴﺭﻴﺔ ، ﻭﻟﻙ ﻤﻁﻠﻕ ﺍﻟﺤﻕ ﻓﻲ ﺭﻓﺽ ﺃﻯ ﺴﺅﺍل ﻻ ﺘﻭﺩ ﻨﻌﺩﻙ ﺒﺄﻥ •
 .ﺍﻹﺠﺎﺒﺔ ﻋﻠﻴﻪ
 ﺃﻤﺎﻨﺘﻙ ﻓﻲ ﺍﻹﺠﺎﺒﺔ ﺘﺴﺎﻋﺩﻨﺎ، ﺤﻴﺙ ﺁﺭﺍﻭﻙ ﻭﺘﺠﺎﺭﺒﻙ ﺘﻬﻤﻨﺎ •
  ﻻ- ﻨﻌﻡ                                  -        ﻫل ﺘﻭﺍﻓﻕ؟     
  
  
  :................................ﺍﻻﻤﻀﺎﺀ
  :...................................ﺍﻟﺘﺎﺭﻴﺦ
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Questionnaire 
Coagulation disturbances in Sudanese HIV/AIDS patients 
Serial No.:.......................................  
Personal data: 
1. Name:…………………………………. State……………………….. 
2. Age (in years)………………………… 3. Tribe:…………………… 
4. Religion                I. Muslim               II. Christian             III. Other 
5. Marital status:     I. Married             II. Single                   III. Divorced  
6. Education:            I. Khalwa             II. Primary               III. Secondary 
                                IV. Higher Secondary              V. University                 VI. No 
7. Employment:    I. Yes                     II. No 
Clinical data: 
8. Duration of illness:     I. Weeks         II. Years          III. Specify……… 
9. Symptoms:     I. Fever           II. Fatigue              III. Loss of weight 
                             IV. Diarrhea             V. Others               (Specify):………….. 
10. Symptoms of bleeding:       I. Haematuria          II. Haemoptysis 
                                                     III. Malaria               IV. Haematmesis 
11. Sign:           I. Pallor             II. Jaundice                        III. Petechiae 
IV. Ecchymosis                       V. Others 
12. Drugs                          Yes                               No                         Stopped 
I. ARV: 
II. Others                                                                                      Specify:……….. 
13. Iner-current infection:     I. Bacterial           II. Viral            III. Fungal       IV. Others 
14. Laboratory investigations: 
I. CBC:…………………….. II. PT:………………………….. III. PTT:……………………………. 
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